Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952896 | 0.84 | ALDH1A1 (0.47) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL27322677 | 0.81 | CYP3A4 (0.43) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL3626567 | 0.81 | TDP1 (0.44) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL30657694 | 0.79 | NFE2L2 (0.46) | MAPK1TDP1CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL27873 | 0.79 | TDP1 (0.54) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL10615043 | 0.79 | TDP1 (0.54) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL28420288 | 0.78 | CYP3A4 (0.41) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL27520419 | 0.78 | GABRA1 (0.43) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL27621561 | 0.77 | TDP1 (0.52) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL2779530 | 0.75 | CYP3A4 (0.50) | MAPK1TDP1CYP3A4TRPA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222314-B2 | Phenyl isocyanate-based urethane acrylates, processes for producing and methods of using the same | BAYER MATERIALSCIENCE AG (DE) | 2012-07-17 | — | — | US | claimed |
| EP-2154129-A1 | Phenylisocyanate based urethanacrylate with high refraction index | Bayer MaterialScience AG (DE) | 2010-02-17 | — | — | EP | claimed |
| EP-2154128-A1 | Phenylisocyanate based urethanacrylates with high refraction index | Bayer MaterialScience AG (DE) | 2010-02-17 | — | — | EP | claimed |
| US-20100036013-A1 | PHENYL ISOCYANATE-BASED URETHANE ACRYLATES, PROCESSES FOR PRODUCING AND METHODS OF USING THE SAME | BAYER MATERIALSCIENCE AG (DE) | 2010-02-11 | — | — | US | claimed |
| EP-2342249-B1 | PREPOLYMER-BASED POLYURETHANE FORMULATIONS FOR PRODUCING HOLOGRAPHIC MEDIA | COVESTRO DEUTSCHLAND AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| EP-2396359-B1 | PHOTOPOLYMER COMPOUNDS AS COMPRESSIBLE FORMULATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9454130-B2 | Photopolymer formulations having the adjustable mechanical modulus GUV | COVESTRO DEUTSCHLAND AG (DE) | 2016-09-27 | — | — | US | disclosed |
| EP-2172502-B1 | POLYETHER-BASED POLYURETHANE FORMULATIONS FOR PRODUCING HOLOGRAPHIC MEDIA | COVESTRO DEUTSCHLAND AG (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-9261778-B2 | Layer composite consisting of a photopolymer film and an adhesive layer | COVESTRO DEUTSCHLAND AG (DE) | 2016-02-16 | — | — | US | disclosed |
| EP-2801094-B1 | COATING COMPOUND MADE OF A PHOTOPOLYMER FILM AND AN ADHESIVE COATING | COVESTRO DEUTSCHLAND AG (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150125784-A1 | PHOTOPOLYMER FORMULATIONS HAVING THE ADJUSTABLE MECHANICAL MODULUS GUV | COVESTRO DEUTSCHLAND AG (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8921012-B2 | Photopolymer formulations having the adjustable mechanical modulus GUV | BAYER MATERIALSCIENCE AG (DE) | 2014-12-30 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| US-6096885-A | EXHIBIT AGONIST ACTIVITY FOR CCK-A RECEPTORS THEREBY ENABLING THEM TO MODULATE THE HORMONES GASTRIN AND CHOLECYSTOKININ IN MAMMALS. | GLAXO WELLCOME INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0785944-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011940-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036013-A1 | PHENYL ISOCYANATE-BASED URETHANE ACRYLATES, PROCESSES FOR PRODUCING AND METHODS OF USING THE SAME | GRHPR, CBR1, C1S | MAPK1 681/4885TDP1 1202/4885CYP3A4 783/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MAPK1 380/4885TDP1 3350/4885CYP3A4 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.